Comparison of Plasma Concentrations of Posaconazole with the Oral Suspension and Tablet in Korean Patients with Hematologic Malignancies

The posaconazole tablet formulation was developed to have improved bioavailability compared to the oral suspension. Here, we compared posaconazole plasma concentration (PPC) with the posaconazole oral suspension versus the tablet in Korean patients undergoing remission induction chemotherapy for hem...

Descripción completa

Detalles Bibliográficos
Autores principales: Suh, Hyeon Jeong, Kim, Inho, Cho, Joo-Youn, Park, Sang-In, Yoon, Seo Hyun, Lee, Jeong-Ok, Koh, Youngil, Song, Kyoung-Ho, Choe, Pyoeng Gyun, Yu, Kyung-Sang, Kim, Eu Suk, Kim, Hong Bin, Bang, Soo-Mee, Kim, Nam Joong, Song, Sang Hoon, Park, Wan Beom, Oh, Myoung-don
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Society of Infectious Diseases and Korean Society for Chemotherapy 2017
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5500269/
https://www.ncbi.nlm.nih.gov/pubmed/28608665
http://dx.doi.org/10.3947/ic.2017.49.2.135
Descripción
Sumario:The posaconazole tablet formulation was developed to have improved bioavailability compared to the oral suspension. Here, we compared posaconazole plasma concentration (PPC) with the posaconazole oral suspension versus the tablet in Korean patients undergoing remission induction chemotherapy for hematologic malignancies. PPC was measured at 3, 8, and 15 days of treatment with the oral suspension (174 patients) or the tablet (40 patients). At all time-points, mean PPC was significantly higher with the tablet compared to the oral suspension. Our findings suggest that posaconazole tablets generate an optimal PPC earlier and in more patients than the oral suspension among Korean patients.

Ejemplares similares